fbpx
Wikipedia

WuXi Biologics

January 01, 1970

WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.

WuXi Biologics
WuXi Biologics Headquarters in Shanghai (2021 Construction)
Company typePublic
SEHK: 2269
Hang Seng Index Component
ISINKYG970081173
Industry
Founded2015; 9 years ago (2015) in Wu Xi City, China
HeadquartersPrimary: 108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu, China, 214092
Area served
Worldwide
Key people
SubsidiariesWuXi Vaccines
CMAB Biopharma Group
Websitewww.wuxibiologics.com
Footnotes / references
[1][2][3][4]

WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing.[5] WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.[6]

As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.[7]

In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.[8]

In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns.[9][10][11] The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy.[12] Members of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party subsequently called for sanctions against WuXi Biologics.[13]

Facilities in Asia edit

Shanghai, China edit

WuXi Biologics has two sites in Shanghai, one in the Shanghai Waigaoqiao Free Trade Zone and the other in Fengxian.[citation needed]

Wuxi, China edit

WuXi Biologics has two sites located in Wu Xi City, China. The Mashan site contains MFG1, MFG2, MFG4 and MFG5.[14] and the Wuxi New Area site contains labs dedicated to the antibody drug conjugate development and production. With 30,000 liters of capacity, MFG2 was the world's largest single-use bioreactor production facility which was replaced in that metric by MFG5 which has a 60,000 liter capacity and opened on February 9, 2021.[15][16]

Hangzhou, China edit

As of March 2021, WuXi Biologics will have two sites in Hangzhou China.

On March 17, 2021, WuXi Biologics announced an equity agreement with Pfizer China to acquire its newly built $350 million Hangzhou global biotechnology center site and facilities (MFG20). Expected to close in the first half of 2021, the deal includes the 50,000 m2 (540,000 sq ft) of facilities which have been GMP operational since 2018 and are equipped with 2X2000L single-use bioreactors with the ability to expand up to 4X2000L single-use bioreactors. Also included in the acquisition are vial filling (DP9) and pre-filled syringe (DP10) fill and finish lines.[17] Opened in 2020 and slated to be GMP-ready in 2021, the Hangzhou site (MFG13) is home to facilities dedicated to the development and GMP manufacture of recombinant proteins and plasmid DNA produced via microbial fermentation along with separate facilities for the development and production of a viral-based vaccine.[15]

Suzhou, China edit

As of March 2021, WuXi Biologics will have two sites located in the city of Suzhou, China.

On March 18, 2021, WuXi Biologics announced a purchase agreement with CBC Group which will allow it to acquire over a 90% interest in CMAB Biopharma Group. The transaction is expected to close in the second quarter of 2021. Along with the controlling stake, WuXi Biologics will also acquire a 7000L bioreactor capacity manufacturing facility (MFG21) in Suzhou and associated liquid and lyophilization (DP21) fill and finish production lines.[18] A second site, opened in 2014 is 108,716 sq ft (10,100.0 m2) and was the first non-governmentally affiliated biosafety testing facility in Asia. The facility performs cell line characterization, viral clearance validation studies, and unprocessed bulk lot release.[15]

Chengdu, China edit

Currently slated to open in 2023, the Chengdu facility (MFG12) will be a 1.3×10^6 sq ft (120×10^3 m2), with an integrated manufacturing center for innovative biologics and dedicated to R&D and commercial-scale bulk API production with an initial bioreactor capacity of 48,000 liters (11,000 imp gal; 13,000 U.S. gal) for commercial production and 5,000 liters (1,100 imp gal; 1,300 U.S. gal) for clinical production.[15][19]

Shijiazhuang, China edit

Currently slated to open in 2022, the Shijiazhuang facility MFG8 will be 884,363 sq ft (82,160.0 m2) and dedicated to development and API manufacturing with an initial bioreactor capacity of 48,000 liters.[15]

Singapore edit

On May 24, 2018, WuXi Biologics announced it will be building a $60 million facility (MFG10) in Singapore which will feature an initial bioreactor capacity of 4,500 liters made up of two 2,000 liter fed-batch reactors and one 500 liter continuous processing perfusion reactor to open in 2023.[15] The project is backed by the Singapore Economic Development Board and will be dedicated to clinical and small volume commercial production as well as early-stage bioprocess development.[20]

Facilities in Europe edit

Leverkusen, Germany Facility edit

On January 17, 2020, WuXi Biologics and Bayer announced an acquisition agreement in which WuXi Biologics would take over the operations and lease a 139,931 sq ft (13,000.0 m2) fill site in Leverkusen, Germany. Based on the agreement, the site would perform the final fill-finish of various biologics products produced by WuXi's API sites, and act as a backup for filling operations for Bayer's Kovaltry anti-hemophilic infusions which are primarily finished in another plant in Berkeley, California.[21]

Wuppertal, Germany Facility edit

On December 21, 2020, WuXi Biologics and Bayer announced a new acquisition agreement for a drug substance (DS) production site for €150 million in Wuppertal, Germany.[22]

Dundalk, Ireland Site edit

Active ingredient production facilities edit

In April 2018,[23] WuXi Biologics announced plans to build a new biologics drug substance manufacturing facility on 26 hectares (64 acres) in Dundalk, Ireland. The project is directly supported by the Irish Government through IDA Ireland, with a cost of approximately $394 million. When completed, the facility will be one of the world's largest plants supporting single-use bioreactors and will help accelerate the development of biologic drugs in Europe.[24] MFG6 will have a perfusion bioreactor capacity of 6,000 liters in a continuous bioprocessing configuration and MFG7 will have a 48,000 liter bioreactor capacity in a traditional fed-batch configuration.[25]

Vaccine production facility edit

In November 2019, WuXi Vaccines, a subsidiary of WuXi Biologics, announced that it would invest an additional $240 million to build a new 167,056 sq ft (15,520.0 m2) vaccine manufacturing facility at the Dundalk, Ireland site. The vaccine site planned includes drug substance manufacturing facilities, drug product manufacturing, Manufacturing Science and Technology Labs as well as Quality Control labs. In February 2020, WuXi Vaccines announced it had signed a 20-year, $3 billion contract with an unidentified "global vaccine leader" to produce one of the unidentified company's vaccine products at the new facility.[26]

Facilities in the United States edit

Massachusetts edit

In May 2020, WuXi Biologics announced that it had secured a deal with the Worcester Business Development Corporation at The Reactory, a master-planned manufacturing hub project in Worcester, Massachusetts. The two-story, 107,000 sq ft (9,900 m2) facility will cost $60 million and will employ 150 when it is completed in 2022. The Worcester City Council granted a 20-year, $11.5 million tax increment financing plan to help seal the deal. The new facility will have 16,000 liters of bioreactor capacity, which will include four 4,000-liter traditional fed-batch units and one 500-liter perfusion-based continuous processing unit and will be named MFG11.[27]

New Jersey edit

In June 2020, WuXi Biologics announced that it had signed a ten-year lease for a 66,000 sq ft (6,100 m2) clinical manufacturing facility (MFG18) in Cranbury, NJ. The facility had previously been leased by Outlook Therapeutics and will install a total of 6,000 liters (1,300 imp gal; 1,600 U.S. gal) of bioreactor capacity, process development, and quality control labs, along with supporting functions.[28]

Pennsylvania edit

In May 2020, WuXi Biologics announced it had leased a 33,000 sq ft (3,100 m2) process development lab in King of Prussia, Pennsylvania at Discovery Labs, a former GlaxoSmithKline manufacturing site.[29]

References edit

  1. ^ "Leadership". WuXi Biologics. from the original on 2020-12-02. Retrieved 2020-12-06.
  2. ^ "Annual Financial Reports". WuXi Biologics. from the original on 2020-12-02. Retrieved 2020-12-06.
  3. ^ "WuXi Vaccines Overviewlanguage=en-US". from the original on 2020-12-03. Retrieved 2020-12-06.
  4. ^ "WuXi Biologics to acquire CMAB Biopharma Grouplanguage=en-US". Retrieved 2021-03-18.
  5. ^ "CHNA ETF Video Series: WuXi Biologics". loncarfunds.com. from the original on 2019-08-14. Retrieved 2019-08-14.
  6. ^ "UPDATE 2-WuXi Biologics prices HK IPO at top as investors seek..." Reuters. 2017-06-06. from the original on 2019-08-14. Retrieved 2019-08-14.
  7. ^ "Global Network". WuXi Press Release. 2020-12-06. from the original on 2020-12-02. Retrieved 2020-12-06.
  8. ^ "Alibaba, Xiaomi, WuXi Biologics to join Hang Seng Index". S&P Global Market Intelligence. 2020-12-06. from the original on 2023-01-10. Retrieved 2020-12-06.
  9. ^ "WuXi Bio Denies Military Ties After Shares Slumped on US Bill". Bloomberg News. 2024-01-29. from the original on 2024-01-29. Retrieved 2024-01-30.
  10. ^ "WuXi AppTec Shares Continue Slide After Company Calls U.S. Draft Bill Findings Inaccurate". The Wall Street Journal. January 28, 2024. from the original on January 29, 2024. Retrieved January 29, 2024.
  11. ^ "WuXi Company Shares Tumble on U.S. Bill Aimed at Chinese Biotech". The Wall Street Journal. February 2, 2024. from the original on February 1, 2024. Retrieved February 2, 2024.
  12. ^ Cheung, Sunny; Hope, Arran; Mattis, Peter (February 9, 2024). "Red Genes: Assessing WuXi AppTec's Ties to the Party-Army-State in China". Jamestown Foundation. from the original on 2024-02-10. Retrieved 2024-02-11.
  13. ^ Martina, Michael (February 12, 2024). "US lawmakers call for sanctions on China's WuXi AppTec biotech firm". Reuters. Retrieved February 12, 2024.
  14. ^ "Facilities". WuXi Biologics. from the original on 2021-01-10. Retrieved 2020-12-06.
  15. ^ a b c d e f "Facilities". WuXi Biologics. from the original on 2020-12-02. Retrieved 2020-12-06.
  16. ^ "The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics" (Press release). PRN. from the original on 2021-02-11. Retrieved 2021-02-15.
  17. ^ "Facilities" (Press release). WuXi Biologics. from the original on 2021-03-17. Retrieved 2021-03-18.
  18. ^ "Facilities" (Press release). WuXi Biologics. from the original on 2021-03-18. Retrieved 2021-03-18.
  19. ^ "WuXi Biologics to build 1.3m-sq-ft manufacturing centre". biopharma-reporter. 16 May 2019. from the original on 2020-10-01. Retrieved 2020-12-06.
  20. ^ Chapman, Sophie (16 May 2020). "WuXi Biologics to construct $60mn facility in Singapore". Manufacturing Digital Magazine. from the original on 11 August 2022. Retrieved 16 May 2022.
  21. ^ "WuXi Biologics taking over Bayer plant..." FiercePharma. 2020-01-16. from the original on 2021-01-21. Retrieved 2020-12-06.
  22. ^ "WuXi Bio lays out €150M to take over Bayer plant in Germany, boosting pandemic supply network". FiercePharma. from the original on 2020-12-22. Retrieved 2020-12-23.
  23. ^ "WuXi Biologics' Biologics Manufacturing Facility, Dundalk, Ireland". Pharmaceutical Technology. from the original on 2019-08-14. Retrieved 2019-08-14.
  24. ^ "Jacobs Wins Contract to Provide Construction Services for WuXi". GEN - Genetic Engineering and Biotechnology News. 2019-06-10. from the original on 2019-06-11. Retrieved 2019-08-14.
  25. ^ "WuXi Biologics Completes Biologics Mfg. Facility in Ireland". Contract Pharma. 2020-03-11. from the original on 2020-09-19. Retrieved 2020-12-06.
  26. ^ "WuXi Vaccines inks $3B manufacturing deal with 'global vaccine leader'". BioPharmaDive. 2020-02-21. from the original on 2020-11-07. Retrieved 2020-12-06.
  27. ^ "WuXi Biologics clinches deal to build first U.S. facility at Boston area hub". FiercePharma. 2020-05-19. from the original on 2020-11-03. Retrieved 2020-12-06.
  28. ^ "WuXi Biologics expands US presence with 6,000L NJ plant". BioProcessIntl. 2020-06-10. from the original on 2020-07-29. Retrieved 2020-12-06.
  29. ^ "Exclusive: Fast-growing biotech firm takes King of Prussia space, plans 100 new jobs". Philadelphia Business Journal. 2020-05-05. from the original on 2021-05-08. Retrieved 2020-12-23.

External links edit

  • Official website  
  • Business data for WuXi Biologics:
    • Bloomberg
    • Google
    • Reuters
    • Yahoo!

January 01, 1970
wuxi, biologics, this, article, contains, content, that, written, like, advertisement, please, help, improve, removing, promotional, content, inappropriate, external, links, adding, encyclopedic, content, written, from, neutral, point, view, february, 2022, le. This article contains content that is written like an advertisement Please help improve it by removing promotional content and inappropriate external links and by adding encyclopedic content written from a neutral point of view February 2022 Learn how and when to remove this message WuXi Biologics is a global Contract Research Development and Manufacturing Organization CRDMO that provides open access integrated technology platforms for biologics drug development WuXi BiologicsWuXi Biologics Headquarters in Shanghai 2021 Construction Company typePublicTraded asSEHK 2269Hang Seng Index ComponentISINKYG970081173IndustryBiotechnology companyPharmaceutical industryFounded2015 9 years ago 2015 in Wu Xi City ChinaHeadquartersPrimary 108 Meiliang Road Mashan Binhu District Wuxi Jiangsu China 214092Area servedWorldwideKey peopleZhisheng Chris Chen Chief executive officer Jijie Gu Chief scientific officer Executive Vice President Weichang Zhou Chief technology officer Executive Vice President Christine Lu Wong Chief financial officer Executive Vice President SubsidiariesWuXi Vaccines CMAB Biopharma GroupWebsitewww wbr wuxibiologics wbr comFootnotes references 1 2 3 4 WuXi Biologics roots date back to 2010 and began building out capabilities and facilities required for biologics discovery development and GMP manufacturing 5 WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017 6 As of 2021 WuXi Biologics has 18 manufacturing sites including ten in China three in the United States two in Ireland two in Germany and one in Singapore 7 In August 2020 WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong 8 In January 2024 WuXi Biologics share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns 9 10 11 The concerns stem from allegations denied by the company that it has worked closely with the People s Liberation Army as a part of the Chinese Communist Party s military civil fusion strategy 12 Members of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party subsequently called for sanctions against WuXi Biologics 13 Contents 1 Facilities in Asia 1 1 Shanghai China 1 2 Wuxi China 1 3 Hangzhou China 1 4 Suzhou China 1 5 Chengdu China 1 6 Shijiazhuang China 1 7 Singapore 2 Facilities in Europe 2 1 Leverkusen Germany Facility 2 2 Wuppertal Germany Facility 2 3 Dundalk Ireland Site 2 3 1 Active ingredient production facilities 2 3 2 Vaccine production facility 3 Facilities in the United States 3 1 Massachusetts 3 2 New Jersey 3 3 Pennsylvania 4 References 5 External linksFacilities in Asia editShanghai China edit WuXi Biologics has two sites in Shanghai one in the Shanghai Waigaoqiao Free Trade Zone and the other in Fengxian citation needed Wuxi China edit WuXi Biologics has two sites located in Wu Xi City China The Mashan site contains MFG1 MFG2 MFG4 and MFG5 14 and the Wuxi New Area site contains labs dedicated to the antibody drug conjugate development and production With 30 000 liters of capacity MFG2 was the world s largest single use bioreactor production facility which was replaced in that metric by MFG5 which has a 60 000 liter capacity and opened on February 9 2021 15 16 Hangzhou China edit As of March 2021 WuXi Biologics will have two sites in Hangzhou China On March 17 2021 WuXi Biologics announced an equity agreement with Pfizer China to acquire its newly built 350 million Hangzhou global biotechnology center site and facilities MFG20 Expected to close in the first half of 2021 the deal includes the 50 000 m2 540 000 sq ft of facilities which have been GMP operational since 2018 and are equipped with 2X2000L single use bioreactors with the ability to expand up to 4X2000L single use bioreactors Also included in the acquisition are vial filling DP9 and pre filled syringe DP10 fill and finish lines 17 Opened in 2020 and slated to be GMP ready in 2021 the Hangzhou site MFG13 is home to facilities dedicated to the development and GMP manufacture of recombinant proteins and plasmid DNA produced via microbial fermentation along with separate facilities for the development and production of a viral based vaccine 15 Suzhou China edit As of March 2021 WuXi Biologics will have two sites located in the city of Suzhou China On March 18 2021 WuXi Biologics announced a purchase agreement with CBC Group which will allow it to acquire over a 90 interest in CMAB Biopharma Group The transaction is expected to close in the second quarter of 2021 Along with the controlling stake WuXi Biologics will also acquire a 7000L bioreactor capacity manufacturing facility MFG21 in Suzhou and associated liquid and lyophilization DP21 fill and finish production lines 18 A second site opened in 2014 is 108 716 sq ft 10 100 0 m2 and was the first non governmentally affiliated biosafety testing facility in Asia The facility performs cell line characterization viral clearance validation studies and unprocessed bulk lot release 15 Chengdu China edit Currently slated to open in 2023 the Chengdu facility MFG12 will be a 1 3 10 6 sq ft 120 10 3 m2 with an integrated manufacturing center for innovative biologics and dedicated to R amp D and commercial scale bulk API production with an initial bioreactor capacity of 48 000 liters 11 000 imp gal 13 000 U S gal for commercial production and 5 000 liters 1 100 imp gal 1 300 U S gal for clinical production 15 19 Shijiazhuang China edit Currently slated to open in 2022 the Shijiazhuang facility MFG8 will be 884 363 sq ft 82 160 0 m2 and dedicated to development and API manufacturing with an initial bioreactor capacity of 48 000 liters 15 Singapore edit On May 24 2018 WuXi Biologics announced it will be building a 60 million facility MFG10 in Singapore which will feature an initial bioreactor capacity of 4 500 liters made up of two 2 000 liter fed batch reactors and one 500 liter continuous processing perfusion reactor to open in 2023 15 The project is backed by the Singapore Economic Development Board and will be dedicated to clinical and small volume commercial production as well as early stage bioprocess development 20 Facilities in Europe editLeverkusen Germany Facility edit On January 17 2020 WuXi Biologics and Bayer announced an acquisition agreement in which WuXi Biologics would take over the operations and lease a 139 931 sq ft 13 000 0 m2 fill site in Leverkusen Germany Based on the agreement the site would perform the final fill finish of various biologics products produced by WuXi s API sites and act as a backup for filling operations for Bayer s Kovaltry anti hemophilic infusions which are primarily finished in another plant in Berkeley California 21 Wuppertal Germany Facility edit On December 21 2020 WuXi Biologics and Bayer announced a new acquisition agreement for a drug substance DS production site for 150 million in Wuppertal Germany 22 Dundalk Ireland Site edit Active ingredient production facilities edit In April 2018 23 WuXi Biologics announced plans to build a new biologics drug substance manufacturing facility on 26 hectares 64 acres in Dundalk Ireland The project is directly supported by the Irish Government through IDA Ireland with a cost of approximately 394 million When completed the facility will be one of the world s largest plants supporting single use bioreactors and will help accelerate the development of biologic drugs in Europe 24 MFG6 will have a perfusion bioreactor capacity of 6 000 liters in a continuous bioprocessing configuration and MFG7 will have a 48 000 liter bioreactor capacity in a traditional fed batch configuration 25 Vaccine production facility edit In November 2019 WuXi Vaccines a subsidiary of WuXi Biologics announced that it would invest an additional 240 million to build a new 167 056 sq ft 15 520 0 m2 vaccine manufacturing facility at the Dundalk Ireland site The vaccine site planned includes drug substance manufacturing facilities drug product manufacturing Manufacturing Science and Technology Labs as well as Quality Control labs In February 2020 WuXi Vaccines announced it had signed a 20 year 3 billion contract with an unidentified global vaccine leader to produce one of the unidentified company s vaccine products at the new facility 26 Facilities in the United States editMassachusetts edit In May 2020 WuXi Biologics announced that it had secured a deal with the Worcester Business Development Corporation at The Reactory a master planned manufacturing hub project in Worcester Massachusetts The two story 107 000 sq ft 9 900 m2 facility will cost 60 million and will employ 150 when it is completed in 2022 The Worcester City Council granted a 20 year 11 5 million tax increment financing plan to help seal the deal The new facility will have 16 000 liters of bioreactor capacity which will include four 4 000 liter traditional fed batch units and one 500 liter perfusion based continuous processing unit and will be named MFG11 27 New Jersey edit In June 2020 WuXi Biologics announced that it had signed a ten year lease for a 66 000 sq ft 6 100 m2 clinical manufacturing facility MFG18 in Cranbury NJ The facility had previously been leased by Outlook Therapeutics and will install a total of 6 000 liters 1 300 imp gal 1 600 U S gal of bioreactor capacity process development and quality control labs along with supporting functions 28 Pennsylvania edit In May 2020 WuXi Biologics announced it had leased a 33 000 sq ft 3 100 m2 process development lab in King of Prussia Pennsylvania at Discovery Labs a former GlaxoSmithKline manufacturing site 29 References edit Leadership WuXi Biologics Archived from the original on 2020 12 02 Retrieved 2020 12 06 Annual Financial Reports WuXi Biologics Archived from the original on 2020 12 02 Retrieved 2020 12 06 WuXi Vaccines Overviewlanguage en US Archived from the original on 2020 12 03 Retrieved 2020 12 06 WuXi Biologics to acquire CMAB Biopharma Grouplanguage en US Retrieved 2021 03 18 CHNA ETF Video Series WuXi Biologics loncarfunds com Archived from the original on 2019 08 14 Retrieved 2019 08 14 UPDATE 2 WuXi Biologics prices HK IPO at top as investors seek Reuters 2017 06 06 Archived from the original on 2019 08 14 Retrieved 2019 08 14 Global Network WuXi Press Release 2020 12 06 Archived from the original on 2020 12 02 Retrieved 2020 12 06 Alibaba Xiaomi WuXi Biologics to join Hang Seng Index S amp P Global Market Intelligence 2020 12 06 Archived from the original on 2023 01 10 Retrieved 2020 12 06 WuXi Bio Denies Military Ties After Shares Slumped on US Bill Bloomberg News 2024 01 29 Archived from the original on 2024 01 29 Retrieved 2024 01 30 WuXi AppTec Shares Continue Slide After Company Calls U S Draft Bill Findings Inaccurate The Wall Street Journal January 28 2024 Archived from the original on January 29 2024 Retrieved January 29 2024 WuXi Company Shares Tumble on U S Bill Aimed at Chinese Biotech The Wall Street Journal February 2 2024 Archived from the original on February 1 2024 Retrieved February 2 2024 Cheung Sunny Hope Arran Mattis Peter February 9 2024 Red Genes Assessing WuXi AppTec s Ties to the Party Army State in China Jamestown Foundation Archived from the original on 2024 02 10 Retrieved 2024 02 11 Martina Michael February 12 2024 US lawmakers call for sanctions on China s WuXi AppTec biotech firm Reuters Retrieved February 12 2024 Facilities WuXi Biologics Archived from the original on 2021 01 10 Retrieved 2020 12 06 a b c d e f Facilities WuXi Biologics Archived from the original on 2020 12 02 Retrieved 2020 12 06 The World s Largest 36 000L Biomanufacturing Line Using Single use Bioreactors Launches GMP Operation at WuXi Biologics Press release PRN Archived from the original on 2021 02 11 Retrieved 2021 02 15 Facilities Press release WuXi Biologics Archived from the original on 2021 03 17 Retrieved 2021 03 18 Facilities Press release WuXi Biologics Archived from the original on 2021 03 18 Retrieved 2021 03 18 WuXi Biologics to build 1 3m sq ft manufacturing centre biopharma reporter 16 May 2019 Archived from the original on 2020 10 01 Retrieved 2020 12 06 Chapman Sophie 16 May 2020 WuXi Biologics to construct 60mn facility in Singapore Manufacturing Digital Magazine Archived from the original on 11 August 2022 Retrieved 16 May 2022 WuXi Biologics taking over Bayer plant FiercePharma 2020 01 16 Archived from the original on 2021 01 21 Retrieved 2020 12 06 WuXi Bio lays out 150M to take over Bayer plant in Germany boosting pandemic supply network FiercePharma Archived from the original on 2020 12 22 Retrieved 2020 12 23 WuXi Biologics Biologics Manufacturing Facility Dundalk Ireland Pharmaceutical Technology Archived from the original on 2019 08 14 Retrieved 2019 08 14 Jacobs Wins Contract to Provide Construction Services for WuXi GEN Genetic Engineering and Biotechnology News 2019 06 10 Archived from the original on 2019 06 11 Retrieved 2019 08 14 WuXi Biologics Completes Biologics Mfg Facility in Ireland Contract Pharma 2020 03 11 Archived from the original on 2020 09 19 Retrieved 2020 12 06 WuXi Vaccines inks 3B manufacturing deal with global vaccine leader BioPharmaDive 2020 02 21 Archived from the original on 2020 11 07 Retrieved 2020 12 06 WuXi Biologics clinches deal to build first U S facility at Boston area hub FiercePharma 2020 05 19 Archived from the original on 2020 11 03 Retrieved 2020 12 06 WuXi Biologics expands US presence with 6 000L NJ plant BioProcessIntl 2020 06 10 Archived from the original on 2020 07 29 Retrieved 2020 12 06 Exclusive Fast growing biotech firm takes King of Prussia space plans 100 new jobs Philadelphia Business Journal 2020 05 05 Archived from the original on 2021 05 08 Retrieved 2020 12 23 External links editOfficial website nbsp Business data for WuXi Biologics BloombergGoogleReutersYahoo Retrieved from https en wikipedia org w index php title WuXi Biologics amp oldid 1216238878, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.